Senda Biosciences, a company that is harnessing nature to program targeted, potent, and tunable medicines, today announced the completion of a $123 million Series C financing, bringing its total funding raised to date to $266 million. Flagship Pioneering, which founded Senda, participated along with new investors, including the Samsung Life Science Fund, Qatar Investment Authority (QIA), Bluwave Capital, and Stage 1 Ventures. Also participating in the financing are current investors, including Alexandria Venture Investments, Longevity Vision Fund, Mayo Clinic, Partners Investment, and State of Michigan Retirement System.

Senda Biosciences is committed to bringing life-changing treatments to patients by harnessing nature's code to program human cells-both from within and from outside-for targeted, potent, and tunable medicines. Senda's proprietary platform includes an mRNA engine and the first-ever atlas of nature-derived programmable systems at the molecular level and across all kingdoms of life-accessing the entire code provided by nature required to program cells. With this platform, Senda is developing a new class of SendRNA™ medicines for infectious, genetic, metabolic, and autoimmune diseases, as well as oncology and powering new frontiers for mRNA therapeutics and vaccines and gene-editing and protein-based therapies.